Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Summary

This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and does not respond to treatment (refractory). Patients must have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.

Conditions

• Advanced Lymphoma
• Advanced Malignant Solid Neoplasm
• Bladder Carcinoma
• Breast Carcinoma
• Cervical Carcinoma
• Colon Carcinoma
• Colorectal Carcinoma
• Endometrial Carcinoma
• Esophageal Carcinoma
• Exocrine Pancreas Carcinoma
• Gastric Carcinoma
• Glioma
• Head and Neck Carcinoma
• Hematopoietic and Lymphoid Cell Neoplasm
• Kidney Carcinoma
• Liver Carcinoma
• Lung Carcinoma
• Lymphoma
• Malignant Uterine Corpus Neoplasm
• Malignant Uterine Neoplasm
• Melanoma
• Multiple Myeloma
• Ovarian Carcinoma
• Prostate Carcinoma
• Rectal Carcinoma
• Recurrent Bladder Carcinoma
• Recurrent Breast Carcinoma
• Recurrent Cervical Carcinoma
• Recurrent Colon Carcinoma
• Recurrent Colorectal Carcinoma
• Recurrent Esophageal Carcinoma
• Recurrent Gastric Carcinoma
• Recurrent Glioma
• Recurrent Head and Neck Carcinoma
• Recurrent Liver Carcinoma
• Recurrent Lung Carcinoma
• Recurrent Lymphoma
• Recurrent Malignant Solid Neoplasm
• Recurrent Malignant Uterine Corpus Neoplasm
• Recurrent Melanoma
• Recurrent Multiple Myeloma
• Recurrent Ovarian Carcinoma
• Recurrent Pancreatic Carcinoma
• Recurrent Prostate Carcinoma
• Recurrent Rectal Carcinoma
• Recurrent Skin Carcinoma
• Recurrent Thyroid Gland Carcinoma
• Refractory Lymphoma
• Refractory Malignant Solid Neoplasm
• Refractory Multiple Myeloma
• Skin Carcinoma
• Thyroid Gland Carcinoma

Interventions

DRUG

Adavosertib

Given PO

DRUG

Afatinib

Given PO

DRUG

Afatinib Dimaleate

Given PO

DRUG

Binimetinib

Given PO

PROCEDURE

Biopsy Procedure

Undergo tumor biopsy

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

DRUG

Capivasertib

Given PO

PROCEDURE

Computed Tomography

Undergo computed tomography (CT)

DRUG

Copanlisib

Given IV

DRUG

Copanlisib Hydrochloride

Given IV

DRUG

Crizotinib

Given PO

OTHER

Cytology Specimen Collection Procedure

Optional correlative studies

DRUG

Dabrafenib

Given PO

DRUG

Dabrafenib Mesylate

Given PO

DRUG

Dasatinib

Given PO

DRUG

Defactinib

Given PO

DRUG

Defactinib Hydrochloride

Given PO

PROCEDURE

Echocardiography Test

Undergo echocardiography (ECHO)

DRUG

Erdafitinib

Given PO

DRUG

Fexagratinib

Given PO

DRUG

Ipatasertib

Given PO

OTHER

Laboratory Biomarker Analysis

Undergo molecular analysis

DRUG

Larotrectinib

Given PO

DRUG

Larotrectinib Sulfate

Given PO

PROCEDURE

Magnetic Resonance Imaging

Undergo magnetic resonance imaging (MRI)

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

BIOLOGICAL

Nivolumab

Given IV

DRUG

Osimertinib

Given PO

DRUG

Palbociclib

Given PO

BIOLOGICAL

Pertuzumab

Given IV

DRUG

PI3K-beta Inhibitor GSK2636771

Given PO

PROCEDURE

Radiologic Examination

Undergo radiologic evaluation

PROCEDURE

Radionuclide Imaging

Undergo nuclear study

BIOLOGICAL

Relatlimab

Given IV

DRUG

Sapanisertib

Given PO

DRUG

Sunitinib Malate

Given PO

DRUG

Taselisib

Given PO

DRUG

Trametinib

Given PO

BIOLOGICAL

Trastuzumab

Given IV

BIOLOGICAL

Trastuzumab Emtansine

Given IV

DRUG

Ulixertinib

Give PO

DRUG

Vismodegib

Given PO

Sponsors & Collaborators

• National Cancer Institute (NCI)

  lead NIH

Principal Investigators

• Keith T Flaherty · ECOG-ACRIN Cancer Research Group

Study Design

Allocation

NON_RANDOMIZED

Purpose

SCREENING

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2015-08-17

Primary Completion

2026-12-31

Completion

2026-12-31

FDA Drug

Yes

Countries

• United States
• Guam
• Puerto Rico

Study Locations